Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.43 |
| ▸ | CTSK | P43235 | 3/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 7/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10054498 | 1.00 | SCN9A (0.45) | SCN9ACTSSCTSKAAK1ATM | |
| SCHEMBL10054499 | 0.89 | SCN9A (0.45) | SCN9ACTSSCTSKAAK1ATM | |
| SCHEMBL10054507 | 0.89 | SCN9A (0.45) | SCN9ACTSSCTSKAAK1ATM | |
| SCHEMBL12849500 | 0.89 | SCN9A (0.45) | SCN9ACTSSCTSKAAK1ATM | |
| SCHEMBL10054447 | 0.87 | CTSS (0.45) | SCN9ACTSSCTSKAAK1ATM | |
| SCHEMBL1509219 | 0.87 | CTSS (0.45) | SCN9ACTSSCTSKAAK1ATM | |
| SCHEMBL2364410 | 0.87 | CTSS (0.45) | SCN9ACTSSCTSKAAK1ATM | |
| SCHEMBL8270606 | 0.86 | SCN9A (0.43) | SCN9ACTSSCTSKAAK1ATM | |
| SCHEMBL10054503 | 0.86 | SCN9A (0.43) | SCN9ACTSSCTSKAAK1ATM | |
| SCHEMBL10054481 | 0.85 | ATM (0.45) | SCN9ACTSSCTSKAAK1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120258960-A1 | NOVEL MULTIFUNCTIONAL PEPTIDASE INHIBITORS, ESPECIALLY FOR MEDICAL USE | IMTM GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| US-20120258960-A1 | NOVEL MULTIFUNCTIONAL PEPTIDASE INHIBITORS, ESPECIALLY FOR MEDICAL USE | IMTM GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | IMTM GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | IMTM GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| EP-2292589-A1 | Novel multifunctional peptidase inhibitors, especially for medical use | IMTM GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | SERPINB1, CMA1, CPA3 | SCN9A 4524/4885CTSS 43/4885CTSK 101/4885 |
| US-20120258960-A1 | NOVEL MULTIFUNCTIONAL PEPTIDASE INHIBITORS, ESPECIALLY FOR MEDICAL USE | PEPD, CTSC, SERPINB1 | SCN9A 2438/4885CTSS 61/4885CTSK 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.